Pharmaceutical News and Articles

New Plan Could Speed Medicare Coverage for Innovative Devices

FRIDAY, April 24, 2026 A new proposal could make it easier for patients to access breakthrough medical devices through Medicare.On Thursday, federal regulators

Former Tobacco Executive Takes CDC Role

FRIDAY, April 24, 2026 A new hire at the U.S. Centers for Disease Control and Prevention (CDC) is drawing backlash from public health experts who worry about hi

Cognitive Impairment Linked to Worse Outcomes in Chronic Kidney Disease

H pitaux de Paris, and colleagues examined the specific impact of CI on adverse outcomes in CKD in a cohort that included 3,033 patients with CKD stage 2 to 5 a

Proximal Hypoglossal Nerve Stimulation Beneficial for Obstructive Sleep Apnea

For adults with moderate-to-severe obstructive sleep apnea (OSA), proximal hypoglossal nerve stimulation (pHGNS) yields a clinically significant response versus

Less Than Half of Pregnant Women With Opioid Use Disorder Receive Meds

Less than half of pregnant women with opioid use disorder (OUD) receive medications for OUD (MOUD) during pregnancy, according to a study published online April

About One-Third of Children and Adolescents Use Dietary Supplements in the U.S.

About one-third of children and adolescents use dietary supplements in the United States, according to a study published online April 24 in Pediatrics Open Scie

Triple Antihypertensive Pill May Lower Incidence of Recurrent Stroke

For patients with intracerebral hemorrhage, treatment with a once-daily pill containing three low-dose antihypertensive agents is associated with a lower incide

Sanofi's Tzield Approved in the U.S. to Delay the Onset of Stage 3 Type 1 Diabetes in Young Children

Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)

Merck (NYSE MRK), known as MSD outside of the United States and Canada, and Eisai today announced results from the Phase 3 LITESPARK-012 trial evaluating combin

Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS

Genentech, a member of the Roche Group (SIX RO, ROP OTCQX RHHBY), announced today new data from the positive Phase III FENhance 1 and 2 studies, which met their